Advanced Cell Technology Announces Completion Of Pre-IND Meeting With The FDA For RPE Therapy For The Treatment Of Retinal Degenerative Disease

Advanced Cell Technology, Inc. (OTCBB:ACTC) announced that it completed discussions with the Food and Drug Administration (FDA) regarding its retinal pigmented epithelial (RPE) cell therapy through a type B, pre-Investigational New Drug (pre-IND) meeting concerning the regulatory pathway and requirements to file an IND to initiate human clinical trials.

More: continued here

Filed under: Eye Health on February 7th, 2008